Ursule Van de Velde

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass

Bart Keymeulen, Melanie Walter, Chantal Mathieu et al. · Diabetologia · 2010 · 313 citations · Full text

Medicine, Endocrinology, Immunology +14

A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes

Bart Keymeulen, André van Maurik, João J. Oliveira et al. · Diabetologia · 2020 · 50 citations · Full text

Pharmacy, Immunology, Pharmacology +17

Preexisting Insulin Autoantibodies Predict Efficacy of Otelixizumab in Preserving Residual β-Cell Function in Recent-Onset Type 1 Diabetes

Simke Demeester, Bart Keymeulen, Leonard Kaufman et al. · Diabetes Care · 2015 · 30 citations · Full text

Life Sciences, Endocrinology, Immunology +17

Minimal Functional β-Cell Mass in Intraportal Implants That Reduces Glycemic Variability in Type 1 Diabetic Recipients

Pieter Gillard, Robert Hilbrands, Ursule Van de Velde et al. · Diabetes Care · 2013 · 28 citations · Full text

Medicine, Endocrinology, Physiology +17

Relationship between glycaemic variability and hyperglycaemic clamp-derived functional variables in (impending) type 1 diabetes

Annelien Van Dalem, Simke Demeester, Eric V. Balti et al. · Diabetologia · 2015 · 26 citations

Medicine, Endocrinology, Physiology +15